Since its IPO in 2021, the narrative surrounding footwear icon Dr Martens PLC (LSE:DOCS) has been so overwhelmingly negative that it’s easy to miss the green shoots of optimism emerging from the business.
While plummeting revenues in the first half filtered through to a pre-tax loss, analysts from broker Peel Hunt noted that the numbers were broadly in line with forecasts.
More importantly, Dr Martens’ sales volumes may have hit the nadir and while the broker’s analysts believe a recovery “will likely be fairly protracted”, the stage could be set for a new year redemption.
Incoming chief executive Ije Nwokorie, who currently serves as chief brand officer after stints as CEO of brand consultancy Wolff Olins and a marketing director at Apple, will be hoping to steer Dr Martens successfully through this redemption arc, although patience will be necessary.
“Overall, the brand is clearly fine, the company is addressing operational challenges, but recovery is a multi-year event,” said Peel Hunt analysts.
Given Dr Martens’ 11% share price rally today, there is clearly a degree of optimism in the market.
Dan Coastsworth, investment analyst at AJ Bell, espoused similarly cautious optimism.
He said: “The bootmaker has a recovery plan and it knows what’s needed to fix the business. It’s now a waiting game for the strategy to play out.
“Half-year results are too early to judge the turnaround efforts, but there is enough to silence the critics and pique investors’ interest.”
Coatsworth said falling revenues and earnings, and a smaller dividend, were “not a surprise".
The reason why the shares have jumped is new guidance for cost savings to hit the top end of previous guidance, inventory is coming down and the company has reported strong sales of new products," he added.
"These nuggets are exactly what’s needed to rebuild credibility with the market".
It will not be an easy task for Nwokorie, although his creative professional background will help in Dr Martens’ marketing efforts in the US, where sales volumes need the most work.
Dr Martens' shares are currently changing hands at 63.79p, which is more than 85% below the 2021 IPO price.